PathKOL
Best in class pathology scoring platform for clinical trials
PathKOL digital reporting system (DRS) software platform allows access to global experts in clinical trials histological endpoints, also known as central reading. This is a crucial component to the success of clinical trials requiring tissue analytics. The real power behind PathKOL is vertical integration with a state of the art, AI-enabled, laboratory with biomarker quantification coupled with high quality, consistent histology in a CLIA/CAP regulated environment. These factors help to de-risk clinical trials biopsies.
Providing you direct access to pathology experts
Pharmaceutical and biotechnology industries: We provide histology support for early stage, Phase 2 and Phase 3 clinical trials. Our recommendation is to engage in partnerships with disease and organ specific expert pathologists as early as possible in the project as this can be key for integrating and developing clinically relevant endpoints and companion biomarkers. Digital pathology and AI integration of biomarkers is important for enhancing detection of therapeutic responsivity via quantitation. We partner with established top pharmaceutical companies and also biotech and pharma startups to help ensure their ultimate success. Clinicians: Specialist pathology services are underutilized and can be critical for enhancing your practice quality and performance. Integration of AI-enabled cutting edge diagnostics can also improve competitiveness.
Pathology Central Reading and Consulting
We have deep expertise in clinical trials pathology central reading for histologic endpoints. We are capable of individual, group (consensus), and real-time reads for rapid recruitment and resulting. We also develop novel scoring systems, manage labs, and provide general pathology consultation.
